Evaluating plasma cytokines in patients with certain blood cancers treated with non-intensive chemotherapy
Official title: Single-center, Biological, Uncontrolled, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 (FMS-like Tyrosine Kinase 3) Ligand and IL6 With a View to Making a First Estimate of Their Prognostic Value on the Outcome of Patients Treated With Non-intensive Chemotherapy Such as Azacytidine for Acute Myelogenous Leukemia (AML), High Risk Myelodysplastic Syndrome (HR-MDS) or Chronic Myelomonocytic Leukemia (CMML)
Run by Nantes University Hospital · NCT06439199 · Data updated 2026-11-12
This study is trying to see if measuring certain proteins in the blood can help predict how well patients with specific blood cancers do when they receive two different types of chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Nantes University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Nantes, Loire-Atlantique) |
| Status | Recruiting |
| Started | September 23, 2024 |
| Main results expected | July 15, 2028 |
| Study ends | December 15, 2029 |
| Registry record updated | September 9, 2026 |
| Trial ID | NCT06439199 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older diagnosed with AML, HR-MDS, or CMML who are receiving non-intensive chemotherapy.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or unable to provide informed consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the plasma cytokine profiles, specifically focusing on FLT3 ligand and IL-6, in patients with Acute Myeloid Leukemia (AML), high-risk myelodysplastic syndromes (HR-MDS), or chronic myelomonocytic leukemia (CMML) who are receiving non-intensive chemotherapy. Patients will be divided into two groups: one receiving Azacytidine and Venetoclax, and the other receiving Azacytidine alone. Cytokine assays will be conducted at various intervals during treatment cycles to assess their predictive value for patient outcomes. The study will follow patients for 12 months from the start of treatment.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of cytokine profiles that predict treatment responses and outcomes in patients with these blood cancers.
How similar studies have gone: While the study focuses on a specific patient population and treatment approach, similar studies have shown that cytokine profiles can be indicative of treatment outcomes in other cancer types.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria : * Age \>=18 years * AML or SMD-HR or CMML in first line or in relapse receiving a hypomethylating agent +/- another molecule or a hypomethylating agent in combination with venetoclax +/- another molecule. * Patient having agreed to participate in the study (information note signature) and having signed the biocollection consent Exclusion Criteria : * No social security or any other regime * Pregnant women or patient unable to take contraception in case of fertility * Breastfeeding women * Minors * Adults under guardianship, curators or safeguard of justice
Where it's running
-
Nantes University Hospital
Nantes, Loire-Atlantique, France Recruiting
Study contacts
- Study coordinator: Alice GARNIER, PH
- Email: alice.garnier@chu-nantes.fr
- Phone: 33 2 44 76 80 81
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Assessing the safety and effectiveness of LP-108 with azacitidine for blood cancers
This study is testing a new combination of LP-108 and azacitidine to see if it helps people with blood cancers like acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia feel better and stay safe during treatment.
-
Combining new treatments for high-risk blood cancers
This study is testing a new combination of two treatments for people with high-risk blood cancers to see if it is safe and effective in improving their condition.
-
Low dose decitabine and venetoclax for treating myeloid cancers
This study is testing a new lower-dose treatment combining decitabine and venetoclax for patients with myeloid cancers who can't handle the usual medications to see if it's easier for them to tolerate.
-
Comparing T Cell Depletion Methods for Blood Cancer Treatment
This study is testing different ways to prevent complications after a stem cell transplant for blood cancer to see which method helps patients stay healthy and cancer-free longer.
-
Evaluating a new treatment for advanced blood cancers
This study is testing a new drug called EP0042 to see if it is safe and effective for people with advanced blood cancers like AML, CMML, and MDS.
-
Testing a new oral medication for blood cancers
This study is testing a new oral medication for blood cancers to see if it works better than the standard treatment for patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.